Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood concentrate may boost healing of jaw bone damage from common drugs

NCT ID NCT07464678

Disease control Sponsor: Poznan University of Medical Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 22 people with jaw bone damage caused by medications for osteoporosis or cancer. They all had surgery to remove the damaged bone. Half also received a gel made from their own blood (platelet-rich fibrin) placed into the wound. The goal was to see if this gel helps the jaw heal better and reduces complications. Results will compare healing and quality of life over 6 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

22 people

The number who actually took part.

Started

Mar 2022

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients diagnosed with medication-related osteonecrosis of the jaw (MRONJ) according to the criteria established by the American Association of Oral and Maxillofacial Surgeons (AAOMS). * patients aged ≥18 years Exclusion Criteria: * Presence of metastases to the bones of the head and neck. * History of hematologic disorders, including leukemia or thalassemia. * Any condition or comorbidity that, in the investigator's judgment, would interfere with the patient's ability to safely participate in the study or comply with the protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Medication-related osteonecrosis of the jaw are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteonecrosis of the jaw

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Medication-related osteonecrosis of the jaw

Contacts and locations

Locations

  • Uniwersytecki Szpital Kliniczny w Poznaniu

    Poznan, Wielkopolska, 60-355 Poznań, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.